Trevi Therapeutics (TRVI) Stock Forecast & Price Target
Score
Trevi Therapeutics, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 2 |
| Buy | 9 |
| Hold | 0 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
11 analysts cover TRVI.
Is Trevi Therapeutics, Inc. a buy or sell?
Of the 11 analysts covering Trevi Therapeutics, Inc., 11 rate it a buy (2 strong buy and 9 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The TRVI consensus label is Buy, beside 11 buy-side ratings and 0 sell-side ratings.
the Trevi Therapeutics, Inc. closes with 11 buy-side ratings and 0 on the sell side. The headcount is Buy.
Reading the Trevi Therapeutics, Inc. forecast
Most of the TRVI coverage agrees: 11 of 11 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.
TRVI coverage is thin at 11 analysts, and one revision moves the average.
Trevi Therapeutics, Inc. forecast questions
What is the TRVI price target?
No average price target is on file for TRVI.
Is Trevi Therapeutics, Inc. a buy or sell?
Of the 11 analysts covering Trevi Therapeutics, Inc., 11 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, which for TRVI is 11 on the buy side, 0 at hold, and 0 on the sell side.
What is the EPS estimate for Trevi Therapeutics, Inc.?
No EPS estimate for the next two fiscal years is on file for Trevi Therapeutics, Inc..
What is the revenue estimate for Trevi Therapeutics, Inc.?
No revenue estimate for the next two fiscal years is on file for Trevi Therapeutics, Inc..
How many analysts cover TRVI?
11 analysts cover TRVI. Their consensus on TRVI is Buy, across those 11.